As filed with the Securities and Exchange Commission on January 22, 2024
Registration No. 333-276622
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Anika Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 04-3145961 | |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) | |
incorporation or organization) | ||
32 Wiggins Avenue | ||
Bedford, Massachusetts | 01730 | |
(Address of principal executive offices) | (Zip code) |
Anika Therapeutics, Inc. 2021 Inducement Plan
(Full title of the plan)
Cheryl R. Blanchard
President and Chief Executive Officer
Anika Therapeutics, Inc.
32 Wiggins Avenue
Bedford, Massachusetts 01730
(781) 457-9000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
With copies to: | ||
Michael H. Bison | David Colleran | |
Goodwin Procter LLP | Anika Therapeutics, Inc. | |
100 Northern Avenue | 32 Wiggins Avenue | |
Boston, MA 02110 | Bedford, MA 01730 | |
(617) 570-1933 | (781) 457-9261 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-276622), originally filed on January 19, 2024 (the “Registration Statement”), is being filed solely to correct an error in Exhibit 99.1 and to file the correct Exhibit 99.1, which due to an inadvertent error occurring during the edgarization process, previously included an incorrect link. This Amendment does not otherwise update, amend or modify any other information, statement or disclosure contained in the Registration Statement. No additional securities are to be registered, and the appropriate registration fees were paid upon filing of the Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, Commonwealth of Massachusetts, as of January 22, 2024.
ANIKA THERAPEUTICS, INC. | |
/s/ Cheryl R. Blanchard | |
Cheryl R. Blanchard | |
President and Chief Executive Officer | |
/s/ Michael L. Levitz | |
Michael L. Levitz | |
Chief Executive Officer and Treasurer | |
(Principal Financial and Accounting Officer) |